496775-62-3

Description

Eltrombopag Olamine is classified as a thrombopoietin receptor agonist (TPO-RA), primarily used to treat low platelet levels, also known as thrombocytopenia. Eltrombopag olamine is a salt of Eltrombopag, which binds to the transmembrane region of the thrombopoietin (TPO) receptor. Hangzhou Huarong Pharm Co., Ltd. established since 2009 , has been always focusing on supplying products and services to our clients in the field of small molecule drug. Huarong Pharm adheres to our vision, our mission, and our value, keeping abreast of the current trend and state-of-the-art science and technologies of the global biopharmaceutical industry to serve our clients to the utmost satisfaction. Our existing advantages have led to our in-depth services for the R&D of small molecule drug discovery.

Use

Eltrombopag Olamine is a small-molecule thrombopoietin receptor agonist used to increase platelet counts in patients with chronic immune thrombocytopenic purpura (ITP), severe aplastic anemia, and thrombocytopenia related to hepatitis C. It stimulates the production of platelets by interacting with the thrombopoietin receptor in the bone marrow. Eltrombopag works by stimulating the JAK/STAT signaling pathway, which increases the production of platelet-forming cells in the bone marrow. It differs from natural thrombopoietin in its binding site on the receptor and does not activate the AKT pathway. Eltrombopag has shown promise in treating thrombocytopenia associated with dengue fever by increasing platelet counts and reducing bleeding risks.